Background
EMBRACE-I was a prospective multicenter observational cohort study (n=1341 across 24 centers) evaluating outcomes and morbidity of MRI-guided image-guided adaptive brachytherapy (IGABT) integrated with concurrent chemoradiotherapy in locally advanced cervical cancer (FIGO 2009 IB–IVA).
Interventions and follow up
Design: Prospective multicenter observational cohort; all patients received cisplatin-based concurrent chemoradiotherapy plus MRI-guided adaptive brachytherapy per GEC-ESTRO recommendations
Primary endpoints: Local control, disease-specific survival, and late morbidity at 5 years
Median follow-up: 51 months
Primary endpoints: Local control, disease-specific survival, and late morbidity at 5 years
Median follow-up: 51 months
Results
5-yr local control: 92% (all stages)
5-yr pelvic control: 87%
5-yr disease-specific survival: 74%
5-yr OS: 74%
Failure pattern: Cancer-specific mortality driven mainly by nodal and distant failure rather than local relapse
5-yr pelvic control: 87%
5-yr disease-specific survival: 74%
5-yr OS: 74%
Failure pattern: Cancer-specific mortality driven mainly by nodal and distant failure rather than local relapse
Adverse events
Genitourinary: Grade ≥3 morbidity 6.8% (predominantly fistula and ureteral stricture)
Gastrointestinal: Grade ≥3 morbidity 8.5% (predominantly fistula and bowel obstruction)
Vaginal: Grade ≥3 stenosis/necrosis 6.3%; Grade 4–5 events rare (<2% per organ)
Gastrointestinal: Grade ≥3 morbidity 8.5% (predominantly fistula and bowel obstruction)
Vaginal: Grade ≥3 stenosis/necrosis 6.3%; Grade 4–5 events rare (<2% per organ)
Conclusions
MRI-guided adaptive brachytherapy integrated with concurrent chemoradiotherapy achieved excellent local control (92% at 5 years) with acceptable late morbidity, establishing IGABT as the modern standard and informing GEC-ESTRO and international guideline recommendations.
Key Limitations
Non-randomized prospective cohort — no direct comparison with 2D/3D brachytherapy within the same study; patient selection and center expertise may limit generalizability; MRI at brachytherapy not universally available in low-resource settings; FIGO 2009 staging used. EMBRACE-II is the next-generation study.
Clinical Context
EMBRACE-I provided the landmark prospective evidence establishing MRI-guided adaptive brachytherapy as the gold standard for locally advanced cervical cancer. Before IGABT, brachytherapy was delivered using 2D X-ray planning with inferior local control and higher morbidity. These data underpin current ESMO and GEC-ESTRO guidelines mandating image-guided brachytherapy for LACC.